{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T03:36:48Z","timestamp":1774669008084,"version":"3.50.1"},"reference-count":11,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1625,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1111\/j.1346-8138.2010.01182.x","type":"journal-article","created":{"date-parts":[[2011,3,21]],"date-time":"2011-03-21T14:37:56Z","timestamp":1300718276000},"page":"1185-1188","source":"Crossref","is-referenced-by-count":8,"title":["Celecoxib-induced erythema multiforme-type drug eruption with a positive patch test"],"prefix":"10.1111","volume":"38","author":[{"given":"Yukiyasu","family":"ARAKAWA","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriaki","family":"NAKAI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norito","family":"KATOH","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,3,21]]},"reference":[{"key":"10.1111\/j.1346-8138.2010.01182.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"917","DOI":"10.2165\/00002018-200528100-00008","article-title":"Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors","volume":"28","author":"La Grenade","year":"2005","journal-title":"Drug Saf"},{"key":"10.1111\/j.1346-8138.2010.01182.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1159\/000051569","article-title":"Allergic skin reaction to celecoxib","volume":"201","author":"Grob","year":"2000","journal-title":"Dermatology"},{"key":"10.1111\/j.1346-8138.2010.01182.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1046\/j.1365-2230.2003.01285_5.x","article-title":"Celecoxib-induced fixed drug eruption","volume":"28","author":"Bandyopadhyay","year":"2003","journal-title":"Clin Exp Dermatol"},{"key":"10.1111\/j.1346-8138.2010.01182.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.0105-1873.2004.00271i.x","article-title":"Cutaneous reaction to oral celecoxib with positive patch test","volume":"50","author":"Alonso","year":"2004","journal-title":"Contact Derm"},{"key":"10.1111\/j.1346-8138.2010.01182.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1159\/000078588","article-title":"Acute generalized exanthematic pustulosis: a case and an overview of side effects affecting the skin caused by celecoxib and other cox-2 inhibitors reported so far","volume":"209","author":"Goeschke","year":"2004","journal-title":"Dermatology"},{"key":"10.1111\/j.1346-8138.2010.01182.x-BIB6|cit6","first-page":"555","article-title":"Acute generalized exanthematous pustulosis caused by celecoxib","volume":"103","author":"Yang","year":"2004","journal-title":"J Formos Med Assoc"},{"key":"10.1111\/j.1346-8138.2010.01182.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/j.1365-4632.2004.02149.x","article-title":"Celecoxib-induced photoallergic drug eruption","volume":"43","author":"Yazici","year":"2004","journal-title":"Int J Dermatol"},{"key":"10.1111\/j.1346-8138.2010.01182.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"521","DOI":"10.3346\/jkms.2008.23.3.521","article-title":"Drug rash with eosinophilia and systemic symptoms (dress) syndrome induced by celecoxib and anti-tuberculosis drugs","volume":"23","author":"Lee","year":"2008","journal-title":"J Korean Med Sci"},{"key":"10.1111\/j.1346-8138.2010.01182.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"174","DOI":"10.2310\/6620.2008.08068","article-title":"Multifocal fixed drug eruption due to celecoxib","volume":"20","author":"Bellini","year":"2009","journal-title":"Dermatitis"},{"key":"10.1111\/j.1346-8138.2010.01182.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0149-2918(00)87238-0","article-title":"Immunologic tolerability profile of celecoxib","volume":"21","author":"Patterson","year":"1999","journal-title":"Clin Ther"},{"key":"10.1111\/j.1346-8138.2010.01182.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1592\/phco.22.8.637.33200","article-title":"Celecoxib-induced erythema multiforme with glyburide cross-reactivity","volume":"22","author":"Ernst","year":"2002","journal-title":"Pharmacotherapy"}],"container-title":["The Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1346-8138.2010.01182.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1346-8138.2010.01182.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T02:40:51Z","timestamp":1625452851000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1346-8138.2010.01182.x"}},"subtitle":["Letters to the Editor"],"short-title":[],"issued":{"date-parts":[[2011,3,21]]},"references-count":11,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2011,12]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1346-8138.2010.01182.x","relation":{},"ISSN":["0385-2407"],"issn-type":[{"value":"0385-2407","type":"print"}],"subject":[],"published":{"date-parts":[[2011,3,21]]}}}